Share:
Pandion Therapeutics Inc (NASDAQ: PAND) shares closed over 133% higher today.
What Happened: Pandion a developer of novel therapeutics targeting autoimmune diseases will be acquired by a subsidiary of drug multinational
Merck & Co, Inc (NYSE: MRK), according to a statement issued Thursday.
Merck is purchasing Pandion for $60 per share in cash, which values the deal at nearly $1.85 billion.
“This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics,” said Dean Y. Li, President Merck Research Laboratories.
Merck will through a tender offer acquire all outstanding shares of Pandion subject to conditions, including the purchase of a majority of the company.